Evidence map›Paper›PMID 35514964›Full record

ArticleFrontiers in immunology2022

Successive Site Translocating Inoculation Improved T Cell Responses Elicited by a DNA Vaccine Encoding SARS-CoV-2 S Protein.

Xiangxiang Tian, Yifan Zhang, Zhangyufan He, Shaoshuai Li, Dongmei Yan, Zhaoqin Zhu, Yanmin Wan, Wanhai Wang

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.4field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. The 2Human vaccines & immunotherapeutics · 2024
    Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Xiangxiang TianDepartment of Medical Laboratory, First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Yifan ZhangDepartment of Medical Laboratory, First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Zhangyufan HeDepartment of Infectious Disease, Shanghai Key Laboratory of Infectious Diseases and Biosafety Emergency Response, National Medical Center for Infectious Diseases, Huashan Hospital, Fudan University, Shanghai, China.
Shaoshuai LiDepartment of Laboratory Medicine, Shanghai Public Health Clinical Center, Shanghai, China.
Dongmei YanDepartment of Immunology, School of Basic Medical, Jiamusi University, Jiamusi, China.
Zhaoqin ZhuDepartment of Laboratory Medicine, Shanghai Public Health Clinical Center, Shanghai, China.
Yanmin WanDepartment of Infectious Disease, Shanghai Key Laboratory of Infectious Diseases and Biosafety Emergency Response, National Medical Center for Infectious Diseases, Huashan Hospital, Fudan University, Shanghai, China.
Wanhai WangDepartment of Medical Laboratory, First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
First Affiliated Hospital of Zhengzhou University · CNHuashan Hospital · CNJiamusi University · CNShanghai Public Health Clinical Center · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A variety of methods have been explored to increase delivery efficiencies for DNA vaccine. However, the immunogenicity of DNA vaccines has not been satisfactorily improved. Unlike most of the previous attempts, we provided evidence suggesting that changing the injection site successively (successively site-translocated inoculation, SSTI) could significantly enhance the immunogenicity of DNA vaccines in a previous study. To simplify the strategy and to evaluate its impact on candidate SARS-CoV-2 vaccines, we immunized mice with either a SARS-CoV-2 spike-based DNA vaccine or a spike protein subunit vaccine

Indexed as

COVID-19Vaccines, DNAAnimalsCD4-Positive T-LymphocytesCD8-Positive T-LymphocytesCOVID-19 VaccinesHumansInterleukin-2MiceProtein SubunitsSARS-CoV-2Spike Glycoprotein, CoronavirusTumor Necrosis Factor-alphaCOVID-19 VaccinesInterleukin-2Protein SubunitsSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2Tumor Necrosis Factor-alphaVaccines, DNAantibody responseDNA vaccineprotein vaccinesuccessive site translocating inoculationT cell response

Identifiers

PMID35514964
PMCPMC9062103
OpenAlexW4224278660

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.